Clin Osteol 2010; 15(3): 88-90

Osteoporosis drugs selectively affect bone strenght parameters: dual effect of strontium ranelateReview articles

P. Ammann

Bone strength is determined by biomechanical parameters such as bone mass, size, shape and tissue quality. Many osteoporosis treat­ ments build bone mass but also change tissue quality. Careful investigation of all determinants of bone strength should be considered in the pathophysiology of osteoporosis and consequently in the selection of proper antiosteoporotic treatment.

Keywords: osteoporosis, microarchitecture, bone quality, strontium ranelate

Published: December 11, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ammann P. Osteoporosis drugs selectively affect bone strenght parameters: dual effect of strontium ranelate. Osteologický bulletin. 2010;15(3):88-90.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Peck WA, Burkhardt P, Christiansen C et al. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94: 646-650. Go to original source...
    2. Kanis JA, Burlet N, Cooper C et al. European guidance for the diagnosis and ma­ nagement of osteoporosis in postmenopausal women. Osteoporos Int 2008;19: 399 428. Go to original source...
    3. Turner CH. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 2002;13:97-104. Go to original source...
    4. Ammann P, Rizzoli R, Meyer JM et al. Bone density and shape as determinants of bone strength in IGF-I and/or pamidronate-treated ovariectomized rats. Osteoporos Int 1996;6:219-227. Go to original source...
    5. Oxlund H, Ejersted C, Andreassen TT et al. Parathyroid hormone (1-34) and (1-84) stimulate cortical bone formation both from periosteum and endosteum. Calcif Tissue Int 1993;53:394-399. Go to original source...
    6. Ejersted C, Andreassen TT, Oxlund H et al. Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats. J Bone Miner Res 1993;8:1097-1101. Go to original source...
    7. Turner CH, Burr DB. Basic biomechanical measurements of bone: a tutorial. Bone 1993;14:595-608. Go to original source...
    8. Kenedi RM. Textbook of biochemical engineering. Glasgow, Blackie, 1980: 39-73.
    9. Ammann P, Rizzoli R, Bonjour JP. Preclinical evaluation of new therapeutic agents for osteoporosis. In: Meunier PJ. Osteoporosis: diagnosis and management. London, Martin Dunitz, 1998:257-273.
    10. Andreassen TT, Jorgensen PH, Flyvbjerg A et al. Growth hormone stimulates bo­ ne formation and strength of cortical bone in aged rats. J Bone Miner Res 1995;10:1057-1067. Go to original source...
    11. Jorgensen PH, Bak B, Andreassen TT. Mechanical properties and biochemical composition of rat cortical femur and tibia after long-term treatment with bio­ synthetic human growth hormone. Bone 1991;12:353-359. Go to original source...
    12. Toromanoff A, Ammann P, Riond JL. Early effects of shortterm parathyroid hor­ mone administration on bone mass, mineral content, and strength in female rats. Bone 1998;22:217-223. Go to original source...
    13. Ammann P, Rizzoli R. Bone strength and its determinants. Osteoporos Int 2003;14:S13-S18. Go to original source...
    14. Bagi CM, DeLeon E, Ammann P et al. Histo-anatomy of the proximal femur in rats: impact of ovariectomy on bone mass, structure, and stiffness. Anat Rec 1996;245:633-644. Go to original source...
    15. Bagi CM, Ammann P, Rizzoli R et al. Effect of estrogen deficiency on cancellous and cortical bone structure and strength of the femoral neck in rats. Calcif Tissue Int 1997;61:336-344. Go to original source...
    16. Bourrin S, Ammann P, Bonjour JP et al. Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bis­ phosphonate or selective estrogen receptor modulator therapy in aged rats. Bone 2002;30:195-200. Go to original source...
    17. Ammann P, Rizzoli R, Slosman D et al. Sequential and precise in vivo measure­ ment of bone mineral density in rats using dual energy X-ray absorptiometry. J Bone Miner Res 1992;7:311-316. Go to original source...
    18. Goldstein SA, Goulet R, McCubbrey D. Measurement and significance of three dimensional architecture to the mechanical integrity of trabecular bone. Calcif Tissue Int 1993;53:127-133. Go to original source...
    19. Sato M, Zeng GQ, Turner CH. Biosynthetic human parathyroid hormone (1-34) effects on bone quality in agend ovariectomized rats. Endocrinology 1997;138:4330 4337. Go to original source...
    20. Arlot M, Jiang Y, Genant HK et al. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 2008;23:215-222. Go to original source...
    21. Rizzoli R et al. Strontium ranelate has a more positive influence than alendronate on distal tibia cortical and trabecular bone microstructure in women with postme­ nopausal osteoporosis. Osteoporos Int 2009;20:165-166. Go to original source...
    22. Busse B, Priemel M, Jobke B et al. Effects of strontium ranelate therapy after long-term bisphosphonate treatment. J Bone Miner Res 2007;22:S484-S485.
    23. Lewis G, Nyman JS. The use of nanoindentation for characterizing the properties of mineralized hard tissues. J Biomed Mater Res B Appl Biomater 2008;87: 286-301. Go to original source...
    24. Hengsberger S, Ammann P, Legros B et al. Intrinsic bone tissue properties in adult rat vertebrae: modulation by dietary protein. Bone 2005;36:134-141. Go to original source...
    25. Ammann P, Bourrin S, Bonjour JP et al. Protein undernutrition-induced bone loss is associated with decreased IGF-I levels and estrogen deficiency. J Bone Miner Res 2000;15:683-690. Go to original source...
    26. Bourrin S, Ammann P, Bonjour JP et al. Dietary protein restriction lowers plasma insulin-like growth factor I (IGF-I), impairs cortical bone formation, and induces osteoblastic resistence to IGF-I in adult female rats. Endocrinology 2000; 141: 3149-3155. Go to original source...
    27. Ammann P, Badoud I, Barraud S et al. Strontium ranelate treatment improves tra­ becular and cortical intrinsic bone tissue quality, a determinant of bone strength. J Bone Miner Res 2007;22:1419-1425. Go to original source...
    28. Ammann P. Bone strength and ultrastructure. Osteoporos Int 2009;20:1081-1083. Go to original source...
    29. Sato M, Bryant HU, Iversen P et al. Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats. J Pharmacol Exp Ther 1996;279:298-305. Go to original source...
    30. Bain SD, Jerome C, Shen V et al. Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants. Osteoporos Int 2009;20:1417-1428. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.